Theravance Inc news

   Watch this stock
Showing stories 1 - 7 of about 7   

Articles published

THRX 14.93 -0.39 (-2.55%)
price chart
Theravance licenses antibiotic tech to Hospira
Biopharmaceutical company Theravance Inc said it licensed its technology to manufacture antibiotic Vibativ to specialty medicines maker Hospira Inc. The company would purchase from Hospira more than a majority of its Vibativ 750 mg dosage form ...
GlaxoSmithKline boosts Theravance stake
Following approval Tuesday by Theravance stockholders, GSK's previously announced acquisition of 10 million shares of Theravance is now complete - meaning GSK owns 25.8 million shares of Theravance common stock. That's 26.7 percent of the total ...
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 Update
Theravance Inc (NASDAQ:THRX): THRX, approximately 10% of the US long portfolio position, was increased marginally this quarter.
Elevation boasts "gold standard" IIb data for COPD therapy
Four months ago San Diego-based Elevation Pharmaceuticals unveiled a $30 million venture round as it mapped out plans to complete an ambitious mid-stage program for its COPD treatment.
Biopharma raising $500K eyes competitive asthma/COPD drug market
Recent U.S. Food and Drug Administration approvals have included Merck's combination drug Dulera, Novartis/Genentech's Xolair and Novartis/Schering-Plough's Foradil, plus a new nondrug treatment called bronchial thermoplasty.
PPG Industries
PPG Industries (PPG - Analyst Report) recently delivered its 7th consecutive quarter of record earnings, prompting a flurry of positive estimate revisions from analysts.
Ambit, Teva announce FDA clearance of CEP-32496
Health Canada approves Theravance's Vibativ for HAP/VAP caused by gram-positive bacteria Regulatory Affairs > News ... Regulatory Affairs > Suppliers ENNOV - Medical Device and Drug Development Compliance Specialists ENNOV INC. (Ennov) ...